Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SLEEP THERAPY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 721 records · Page 40Linked to original sources
PubMed1996

Ambulatory blood pressure on and off continuous positive airway pressure therapy for the sleep apnea/hypopnea syndrome: effects in "non-dippers".

Ambulatory blood pressure (BP) monitoring was performed in 13 patients with the sleep apnea/ hypopnea syndrome (SAHS) during a randomized, placebo controlled crossover trial of the effects of continuous positive airway pressure (CPAP) therapy. BP was monitored at half-hourly intervals for a 24-hour period both on CPAP and on an oral placebo, each given for a minimum of 3 weeks. Objective effective CPAP use averaged 4.3 hours per night. Weight and anti-hypertensive medications remained stable over the study period. Systolic, diastolic and mean arterial BP for 24-hour, daytime and nighttime periods were not significantly different on placebo compared to CPAP. Those patients with no significant overnight fall in BP on placebo ("non-dippers") showed a significant improvement in daytime mean arterial BP on CPAP (98 +/- 4 mm Hg) compared to placebo (102 +/- 4 mm Hg; p = 0.01). These findings, in a well-controlled trial, suggest that BP is not reduced by CPAP in a heterogeneous group of SAHS patients, but it may be selectively improved in those patients most at risk for cardiovascular morbidity and mortality.

Adult↗
PubMed2003

Acupuncture therapy for sleep-related laryngospasm.

Sleep-related laryngospasm is a rare disorder that may cause severe disablement. It refers to episodic arousal from sleep with a sense of suffocation followed by stridor. This phenomenon, which is caused by laryngospasm, is probably secondary to gastroesophageal reflux. The reflux is the target for current treatment of this serious disorder. Treatment by acupuncture for sleep-related laryngospasm has not been previously reported in the English medical literature. We describe a previously healthy patient with sleep-related laryngospasm caused by gastroesophageal reflux refractory to current medical treatment who was treated successfully using acupuncture.

Acupuncture Therapy↗
PubMed1994

[Nasal positive pressure ventilation (nCPAP) in therapy of obstructive sleep apnea: acceptance by 50 patients].

In a prospective study between 1989 and 1993, 50 patients (45 males, 5 females, mean age: 58.4 years; mean AHI = 37.8/h) suffering from obstructive sleep apnoea were examined. They underwent nocturnal polysomnography and were provided nightly treatment with nasal CPAP (Respironics Sleep-Easy III und REMSTAR, Respironics Inc, Monroeville, PA). 41 patients were given primary treatment with nCPAP. Nine patients were secondarily treated with a nCPAP mask after other modalities of therapy (weight reduction, mandibular positioning appliance, nasal surgery, uvulopalatopharyngoplasty) had been applied without success. All patients were controlled in the sleep laboratory nine to fourty-two months (mean: 18 months) after the masks were fitted. A questionnaire was used to evaluate subjective complaints, use of the CPAP mask, technical problems, partner's acceptance of the mask etc. 46 patients wore the mask on an average of 6.2 nights per week and 6.5 hours per night. These self-reported data from the questionnaire correlated only in 85 per cent of the cases with the data provided by the time clock installed in the CPAP machine. The long-term compliance with nCPAP of the studied group was 92 per cent. Four patients returned their masks within two months. It was possible to provide sufficient respiration to more than 90% of the patients using an average pressure between 7 and 8 cm water column. Respiration presented no problems for all six patients who had previously been treated with uvulopalatopharyngoplasty in our hospital. Despite the mask 41 patients slept with their partner in a common room.

Adult↗
PubMed1989

[Transtracheal oxygen therapy in obstructive sleep apnea syndrome].

In a prospective trial we studied the effect of nocturnal low-flow oxygen administration in 10 consecutive patients with obstructive sleep apnea. In 5 patients the clinical symptoms disappeared completely under nasal oxygen administration and hypoxic episodes decreased from an average of 28 to 3 per hour. In the remaining 5 patients nasal oxygen alone was not sufficiently effective. After insertion of a transtracheal catheter for nocturnal oxygen delivery, however, in 4 of these 5 patients (one patient refused the procedure) clinical symptoms improved and hypoxic episodes were reduced to 3 per hour (48/h without oxygen, 34/h with nasal oxygen). The favourable effect of transtracheal oxygen therapy may be due to the improved oxygenation provided by this technique, as well as to a "pneumatic splint" as a result of increased positive pressure in the central airways during prolonged apneic episodes. Thus, transtracheal oxygen therapy can be considered an efficient alternative to nasal CPAP in patients with severe obstructive sleep apnea syndrome.

Adult↗
PubMed2004

Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis.

BACKGROUND: Increased nasal airflow resistance (NAR) may contribute to the pathophysiology of obstructive sleep apnoea syndrome (OSAS) but studies investigating the effects of relieving nasal obstruction in OSAS have produced differing results. There are no reports of intranasal corticosteroid therapy in adult OSAS patients with reversible nasal obstruction. METHODS: We evaluated an intranasal corticosteroid, fluticasone propionate, in 24 consecutive snorers with associated rhinitis using a randomised, placebo controlled, crossover design. Patients underwent polysomnography, snoring noise, and NAR measurements at baseline and after each 4 week treatment period. RESULTS: Twenty three patients completed the protocol and were divided into an apnoeic group (group A; 13 patients) and a non-apnoeic snoring group (group S; 10 patients) based on an apnoea-hypopnoea frequency (AHI) of > or =10/h or <10/h. AHI was significantly lower following treatment with fluticasone than with placebo in the total population (median (quartile range) 11.9 (22.6) v 20 (26.3); p<0.05) and in group A (23.3 (21.3) v 30.3 (31.9); p<0.05). Median (95% confidence interval) within subject differences for AHI were -3.2 (-17.7 to -0.2) in the total population and -6.5 (-29.5 to 1.8) in group A. NAR was also lower on fluticasone (2.74 (1.21) v 3.27 (1.38), p<0.01), within subject difference being -0.45 (95% CI -0.87 to -0.21). The changes in AHI and NAR in group A were significantly correlated (r=0.56; p<0.05). Snoring noise and sleep quality were unchanged but daily diary records indicated subjective improvements in nasal congestion and daytime alertness with fluticasone (p<0.02). CONCLUSIONS: Intranasal fluticasone is of benefit to some patients with OSAS and rhinitis. The data suggest that this form of nasal obstruction may contribute to the pathophysiology of OSAS.

Administration, Intranasal↗
PubMed2006

[Therapy for sleep-related breathing disorders using positive airway pressure. Data from an HNO sleep laboratory].

BACKGROUND: Computer-assisted cardiopulmonary polysomnography is generally required to differentiate common snoring from serious sleep-related breathing disorders (SRBD) such as sleep apnea. METHODS: This study investigates data from 2,683 diagnostic and therapeutic cardiopulmonary polysomnographies of 1,087 patients over the period 2003-2004. Indications and efficacy of therapy using positive airway pressure (PAP) in SRBD are analyzed as well as alternative procedures. RESULTS: Of the 1,087 patients, 260 (23.9%) needed PAP therapy. In 61% of the patients CPAP-therapy was applied, 19% needed Bi-PAP-ST and 10% Bi-PAP-S-therapy. A total of 91 patients (8.4%) were treated with alternative procedures, partially combined with positive airway pressure. In 760 patients (69.9%) PAP-therapy was controlled or SRBD was excluded. CONCLUSION: There are no generally accepted guidelines for the therapy of SRBD. Indications for conservative and/or surgical procedures in the treatment have to be determined individually, depending on polysomnographic findings, subjective discomfort and physical comorbidities of the patients.

Adolescent↗
PubMed2005

Thyroxine replacement therapy reverses sleep-disordered breathing in patients with primary hypothyroidism.

BACKGROUND AND PURPOSE: Anecdotal reports suggest that sleep-disordered breathing (SDB) is common among patients with primary hypothyroidism. This study was undertaken to determine the prevalence of SDB and to evaluate the effect of thyroxine replacement therapy on SDB in patients with primary hypothyroidism. PATIENTS AND METHODS: Fifty consecutive newly diagnosed, untreated symptomatic patients with primary hypothyroidism (age: 34+/-11 years; males: 21 [42%]) were prospectively studied. Physical examination, anthropometry, fasting blood glucose and serum lipids were performed in all patients at baseline. Polysomnography was done at baseline in all patients and was repeated after adequate thyroxine replacement in those who had SDB. RESULTS: SDB defined as apnea-hypopnea index (AHI) > or =5 was present in 15 patients (30%) at baseline and was reversible in 10 of the 12 patients evaluated following thyroxine replacement therapy (P=0.006). Thyroxine replacement therapy was associated with improvement in findings that reflect a compromised upper airway, such as macroglossia (4 [33%] vs. 1 [8%]; P=0.083), myoedema (5 [42%] vs. 1 [8%]; P=0.046) and facial puffiness (10 [83%] vs. 1 [8%]; P=0.003). CONCLUSIONS: Reversible SDB is common among patients with primary hypothyroidism. Changes in upper airway anatomy resulting from hypothyroidism probably contribute to the development of SDB in these patients.

Adult↗
PubMed1993

[Theophylline in therapy of obstructive sleep apnea?].

We examined the effect of 375 mg theophylline at night in 95 patients (14 women, 81 men) with obstructive sleep apnoea. The apnoea-hypopnoea index decreased significantly from 20.9 +/- 17.2 to 13.5 +/- 15.8/hour, the nadir of oxygen saturation increased from 80.6 +/- 8.5 to 82.4 +/- 8%. A survey of the longterm effects of theophylline in 16 initially responding patients revealed after 31-922 (190 +/- 217) days therapy no statistically significant change of the apnoea-hypopnoea index; however, the nadir of oxygen saturation was lower compared to the beginning of the therapy (83.8 +/- > 79.3 +/- 7.6%). We believe that theophylline is useful in single cases of patients with obstructive sleep apnoea, but is necessary to reconfirm the positive effect.

Adult↗
PubMed1996

Long-term compliance with CPAP therapy in obstructive sleep apnea patients and in snorers.

A prospective study aimed at objectively evaluating compliance with nasal continuous positive airway pressure (CPAP) treatment was conducted in 728 obstructive sleep apnea [OSA; apnea/hypopnea index (AHI) > 15 events/hour] patients and 98 nonapneic snorers (AHI < or = 15 events/hour). Five-hundred seventy-five OSA patients and 33 nonapneic snorers underwent CPAP therapy and were followed-up for an average of 1,176 +/- 38 days (27 to 4,203 days). Compliance to treatment was measured by the mean rate of use of the CPAP device obtained from a built-in time counter. Acceptance of treatment was measured using Kaplan-Meier's model. The acceptance of CPAP was greater than 90% at 3 years and greater than 85% at 7 years in OSA patients. It was greater than 60% at 3 years in nonapneic snorers. The mean rate of CPAP use was 5.7 +/- 1.8 hours/day in OSA patients and 5.6 +/- 1.4 hours/day in snorers who were still on CPAP on October 1, 1995. It was correlated positively with age, body mass index, and AHI, and it was correlated negatively with daytime partial pressure of oxygen (PaO2), forced expiratory volume in 1 second (FEV1), and vital capacity in the group of OSA patients. This study shows that CPAP therapy is reasonably accepted by OSA patients as well as by nonapneic snorers. Both within and between groups, objective disease severity (as measured by the respiratory event index and daytime and nighttime hypoxemia), rather than patients' symptoms or complaints, seemed to play a role in the quality of compliance to treatment.

Body Mass Index↗
PubMed2005

[Combination therapy for severe sleep apnea syndrome].

We assessed the treatment of severe SAS (sleep apnea syndrome) patients who had an AHI (apnea hypopnea index) over 100. Eleven (3.3%) of the 374 patients who came to our hospital between May 2002 and December 2003 had an AHI over 100. They received CPAP (continuous positive airway pressure) therapy as initial therapy, and the AHI recovered within normal limit in the five patients who did not have tonsillar hypertrophy. The other six patients had tonsillar hypertrophy, and the effect of CPAP was poor. Two of the six patients with tonsillar hypertrophy, underwent UPPP (uvuropalatopharyngoplasty), and CPAP become effective postoperatively. These results indicate that combined treatment by CPAP and surgery is an effective means of treating severe SAS with tonsillar hypertrophy.

Adult↗
PubMed1997

[Is SnorEx also ApneaEx? A study with a new intra-oral prosthesis as a form of therapy of obstructive sleep apnea syndrome].

UNLABELLED: In recent years different kinds of dental devices have been advocated for treating sleep apnoea. In this study we report on our results with a kind of prosthesis ("Snor-Ex", DEPITA, 29336 Nienhagen) designed to relieve upper airway obstruction in sleep in pulling forward the tongue by a truss pad positioned in the posterior area of the tongue. We performed the study to test the effectiveness of the device in reducing the number of obstructive events. PATIENTS: 23 patients with OSA (22 male, age: 53.7 +/- 8.6 years, Body mass index: 31.1 +/- 3.9 kg/m2, Apnoea index: 33.5 +/- 18.4, Respiratory disturbance index: 45.6 +/- 19.7, mean apnoea duration: 20.4 +/- 4.4 sec) were included. STUDY DESIGN: Before the study was started, polysomnography was performed and the OSA associated symptoms/claims were standardised with the help of visual analogue scales (VAS). The prosthesis were made by the dental laboratory. Between the 28th and 42nd day after beginning with the study the patients had to come to the hospital for control. The effect of the therapy was documented only by a further polysomnography in patients who could sleep for at least 2.5 hours with the prosthesis. The effects of the device on changing OSA-associated symptoms and snoring were reevaluated by the above mentioned VAS. During the control the patients were divided into non-responders (NR) and responders (R) according to the results. RESULTS: The NR prevail in the study with 75% (17/23). They are characterised by inacceptable loco-regional side effects of the prosthesis, missing improvement of the state of daytime wellbeing and constant obstructive events. Only 25% of the patients are R. They locally tolerated the prosthesis, which is the precondition for long-term therapy. The severity of OSA diminished. Snoring also diminished significantly. CONCLUSION: According to our results the insufficient acceptance and the low effectivity of the SnorEx-prosthesis preclude large-scale indication for OSA patients. The prosthesis should not be prescribed without contacting a sleep lab.

Adult↗
PubMed2004

The effects of bright-light therapy on actigraphical measured sleep last for several weeks post-treatment. A study in a nursing home population.

We investigated the time-course of nocturnal actigraphic measures, following the termination of bright-light therapy for sleep disturbances in demented nursing home patients. From an earlier study, 11 nursing home patients (86 +/- 9 years, Mini-Mental Status Examination score 12 +/- 4) with actigraphically measured sleep efficiency < 85%, were recruited to morning bright-light treatment (6000-8000 lux) 2 h per day for 14 days. Actigraphic measures were registered at pretreatment, treatment and at four monthly post-treatment periods. Each actigraphic recording period consisted of seven consecutive days. Sleep improved substantially with treatment; sleep efficiency increased from 73% to 86% and total nocturnal wake time was reduced by nearly 2 h. During the 16 weeks post-treatment period, actigraphic measures gradually returned to pretreatment levels. Sleep efficiency remained significantly higher than the pretreatment level 4 weeks after treatment termination. Sleep onset latency remained significantly reduced up until 12 weeks post-treatment. This study supports previous findings of beneficial effects of bright-light therapy for sleep disturbances in demented nursing home patients. Furthermore, these results are the first to suggest that post-treatment effects of short-term bright-light therapy may last longer than previously assumed.

Aged↗